Allergan (AGN) Announces Rapastinel Received FDA Breakthrough Therapy Designation for Adjunctive Treatment of MDD
Tweet Send to a Friend
Allergan plc. (NYSE: AGN), a leading global pharmaceutical company today announced that its Phase III ready investigational medication rapastinel ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
